A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

Researchers at the Wuhan Institute of Virology have detected a new coronavirus in bats that is capable of entering human ...

COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that ...

Background: Nirmatrelvir-ritonavir is an oral treatment for SARS-CoV-2 infection in patients who are at high risk of developing severe COVID-19 disease. This antiviral has proven to significantly ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections. Use of these medications ...

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. In a small study, patients with the syndrome were ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

为解决疫苗和抗病毒药物预防新冠重症及死亡的时变效应不明确问题，香港大学研究人员开展相关研究。结果发现两者保护效力随时间变化，接种多剂疫苗有效但第四剂后有衰减，口服抗病毒药 5 天内使用效果好。对优化抗疫策略意义重大，推荐阅读。

Prescribing guidelines and the benefits and risks of nirmatrelvir/ritonavir for COVID patients ...